New hope for sickle cell: Half-Matched transplants aim to cut complications

NCT ID NCT07616154

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a stem cell transplant from a half-matched family donor for children and young adults with sickle cell disease. The goal is to control the disease while reducing serious side effects like graft-versus-host disease. Up to 45 participants will receive a special drug combination to help their body accept the new cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
stem cell transplant from a half-matched family donor
What this could lead to
If successful, this approach could offer a safer way to control sickle cell disease without needing a perfectly matched donor, reducing complications like graft-versus-host disease.
What could go wrong
This is an early phase 2 trial with only 45 participants, so results may not apply to everyone. The transplant still carries risks of rejection, infection, and side effects from chemotherapy and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • St Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.